

1 **Enacting Process Changes to Improve Outcomes in Idiopathic Pulmonary Fibrosis: A**
2 **Quality Improvement Education Initiative**

3

4 **ABSTRACT**

5 **Introduction.** Idiopathic pulmonary fibrosis (IPF) is a rare and fatal pulmonary disease that
6 many clinicians find challenging to recognize and diagnose. The aim of this study was to
7 evaluate a quality improvement education (QIE) intervention designed to improve provider
8 performance on quality measures.

9

10 **Methods.** The project aimed to raise the index of suspicion for IPF; improve the diagnostic
11 process via a stepped work-up; and shorten referral time. We assessed baseline clinic data in
12 primary care practices with no pulmonary service line; designed and implemented an educational
13 intervention to address QI deficits; and evaluated QI data using a pre-post comparative design.
14 Sites participated in regularly scheduled conference calls intended to facilitate interaction and
15 maintain the QI cycle by reporting progress in data collection.

16

17 **Results.** A significant increase in accuracy of SOB diagnosis coding (59% vs 35%) occurred and
18 fewer patients had an inaccurate code for chronic cough (40% vs 63%). The number of average
19 days decreased between first presentation in primary care and diagnostic assessment and time to
20 referral decreased by 7 days for cardiology and 4 days for pulmonology.

21

22 **Discussion.** This QIE intervention raised the local index of suspicion for IPF; increased the
23 number of patients identified with SOB by 24%; improved accuracy of documentation for SOB

24 and chronic cough diagnosis coding; and reduced miscoding for chronic cough. QIE offers an
25 effective intervention to improve processes that support timely referral to pulmonology and
26 earlier consideration of therapy for patients with IPF.

27

28 **Keywords.** Idiopathic pulmonary fibrosis, quality improvement education, process change,
29 primary care

30

31 **BACKGROUND**

32

33 Idiopathic pulmonary fibrosis (IPF) is a rare and fatal type of chronic fibrosing interstitial
34 pneumonia of unknown cause.^{1,2} Both the prevalence and incidence of IPF are more common
35 among men than women and increase with advancing age.³ The disease course of IPF varies, and
36 includes acute exacerbations that can be rapid and unpredictable. Risk factors for IPF include a
37 history of tobacco smoking, occupational and environmental factors, and family history. Overall,
38 IPF has an extremely poor prognosis, considerable impact on patient quality of life, and an
39 average survival time of three to five years from time of diagnosis.^{2,4-6} Although there are no
40 curative therapies for IPF, nintedanib and pirfenidone are associated with slowing disease
41 progression, while lung transplantation is considered an effective intervention for prolonging
42 survival.⁷⁻⁹ Once lung function is lost, it is unrecoverable and therefore the earlier detection of
43 IPF enables the earlier consideration of therapy and facilitates the preservation of lung function.
44 Hence, timely evaluation and early diagnosis are imperative for positive outcomes in IPF;
45 however, the presentation of IPF is often insidious and the average delay between symptom

46 onset and diagnosis is one to two years.¹⁰ IPF is also frequently misdiagnosed as chronic
47 obstructive pulmonary disease (COPD), bronchitis, emphysema, asthma, or heart disease.^{11,12}

48

49 Patients with symptoms of IPF often present in primary care. Key symptoms include dyspnea on
50 exertion/shortness of breath (SOB) and chronic cough, yet these are easily confused with
51 symptoms of more common diseases, such as COPD, bronchitis, asthma, or heart failure.¹¹⁻¹³

52 Therefore the key to diagnosis is the stepwise discrimination between IPF and other common
53 respiratory and cardiovascular causes of SOB, as well as differentiation from other interstitial
54 lung diseases (ILDs), including immunologic diseases, as well as inhalational, infectious, or
55 neoplastic conditions.¹⁴ Diagnostic tools available to primary care providers that might support a

56 diagnosis of IPF include spirometry, chest x-ray (CXR), echocardiogram, and high-resolution
57 computed tomography (HRCT) scan of the chest.¹⁴ The presence of pulmonary or coronary

58 disease risk factors generally drive the direction and sequence of diagnostic testing in a primary
59 care setting. In patients with coronary heart disease presenting with chronic cough and/or

60 exertional dyspnea, tests such as chest x-ray, echocardiogram, and stress testing should be used
61 to exclude non-respiratory causes of breathlessness, such as heart failure, ischemic heart disease

62 and pulmonary hypertension. Chest x-ray and pulmonary function tests such as spirometry can

63 be used to confirm or exclude a diagnosis of COPD in patients who present with any

64 combination of breathlessness and chronic cough. Spirometry can differentiate between

65 obstructive disease as is seen typically in COPD and restrictive disease which usually (but not

66 always) accompanies ILD, including IPF.

67

68 A stepped diagnostic work-up that excludes non-respiratory causes of breathlessness will usually
69 provide a clue to the presence of ILD, either through changes seen on the CXR or if obtained,
70 through changes seen on HRCT. A history of exposure to risk factors may further raise the index
71 of suspicion for IPF, but such risk factors may not be present in all cases. Referral to a
72 pulmonologist for further evaluation should be the next step, which unfortunately is sometimes
73 delayed. Specifically, a lack of clinician familiarity with ILD and IPF symptoms poses a barrier
74 to initiating a stepped work-up and may contribute to misdiagnosis, which can lead to
75 inappropriate treatment, unchecked disease progression, impaired quality of life, and lower
76 survival rates.¹²

77

78 Quality improvement combined with continuing education (QIE) offers potential to improve
79 provider performance on quality measures and so enhance care coordination and improve patient
80 outcomes.¹⁵ We designed and implemented a QIE initiative to improve the diagnosis and
81 subsequent care of patients with IPF. Our overall goals were to reduce time to diagnosis and time
82 to specialist referral for patients who present in the primary care setting with new onset or
83 unexplained SOB and/or unexplained cough.

84

85 **METHODS**

86 We adopted a Plan-Do-Study-Act (PDSA) methodology to identify delayed diagnosis of IPF as a
87 QI problem, assess baseline clinic data, design and implement an educational intervention, and
88 evaluate QI data. *Planning* involved developing a gap analysis to identify the QIE goals, target
89 metrics, data collection process, and assessment of current site processes related to each metric.
90 *Doing* involved identifying and incorporating team and system practice changes and data entry.

91 *Studying* occurred during regularly scheduled web conferences among all sites, where weekly
92 data, experiences, challenges, and suggestions for improvement were shared. *Acting* occurred
93 when individual sites decided upon their own course correction and began the PDSA cycle again.

94

95 The QI project was conducted at primary care practice settings using a pre-post comparative
96 design and is reported according to the SQUIRE checklist.¹⁶ The study was approved by the
97 Western Institutional Review Board. Organizational culture is a critically important component
98 of successful QI process change; therefore, the inclusion criteria for this pilot program were as
99 follows:

100

- 101 1. Small to medium primary care practices with no hospital affiliation.
- 102 2. Practices with no pulmonary service line.
- 103 3. Practices located within or bordering Ohio and/or the lower Mississippi River as these
104 states have been identified by the US Centers for Disease Control and Prevention with the
105 highest prevalence of COPD.¹⁷
- 106 4. Men and women patients aged 60 years and older with any smoking history who present
107 with new onset or unexplained SOB and/or unexplained cough.
- 108 5. Ability to establish a QIE Champion.
- 109 6. Capability to invest resources and time for training on quality metrics and data collection.

110

111 **Intervention**

112 *Site Selection, Support, and Education*

113 We identified sites from health systems and hospitals across the Southeast US. The sites included
114 small to medium sized primary care practices with no hospital affiliation that were located within
115 or bordering Ohio and/or the lower Mississippi River. We managed onboarding, training, and
116 helped identify a clinical and operational Champion within each site to serve as the primary site
117 contact, coordinate education webcasts, disseminate information, and provide ongoing
118 motivation. Practice managers were involved as operational Champions at each site. The QIE
119 initiative did not require clinicians to perform new administrative or data entry tasks. Only
120 Champions entered patient, physician, and site-level data into a custom database on a weekly
121 basis. We audited data entry to identify timeliness of entry issues, accuracy of data, etc. Sites
122 participated in regularly scheduled Web-based conference calls intended to facilitate interaction
123 and maintain the QIE cycle by reporting progress in practice-level and site-level data collection.

124

125 We designed the educational intervention in collaboration with faculty with expertise in IPF to
126 achieve the following goals:

127

- 128 1. Increase PCPs' awareness and understanding of IPF epidemiology, symptoms, and
129 clinical manifestations;
- 130 2. Improve the IPF diagnostic process for patients who present in a primary care setting
131 with new onset or unexplained SOB and/or unexplained cough;
- 132 3. Recognize the importance of considering IPF early in the work-up;
- 133 4. Order and interpret appropriate tests to complete a stepped diagnostic work-up; and
- 134 5. Refer patients to pulmonary and/or cardiology specialists for further evaluation.

135

136 Following review of the importance of national guidelines and measures, as well as the initiative
137 objectives, an education webcast was delivered live at each site between December 2017 and
138 March 2018. The educational webcast was certified to provide continuing education credit (1
139 hour) for physicians (ACCME) and nurses (AANP and ANCC). During live webcasts
140 participants were able to ask faculty questions about IPF. Following education exposure,
141 participants discussed the site's current practices and protocols, target outcomes, a redesign of
142 current care delivery, new organizational protocols, approaches to overcoming barriers, and
143 unanswered questions. Lastly, the site reviewed the data collection and reporting process.

144

145 **Measures**

146 The project objectives were as follows:

- 147 1. Raise the index of suspicion for IPF in a primary care setting
- 148 2. Improve the process of exclusion of other known causes of cough and new onset or
149 unexplained SOB
- 150 3. Improve diagnosis via a stepped work-up
- 151 4. Shorten time to referral for patients with concerning symptoms to a pulmonologist

152

153 We identified a range of process metrics based on literature review and input from expert
154 faculty:

- 155 1. Diagnosis of shortness of breath or chronic cough
- 156 2. Time to Spirometry or PFT within primary care office or time to referral
157 for Pulmonary Function Testing (PFT)
- 158 3. Time to Chest X-ray within primary care office or time to referral for

159 Chest X-ray at another site

160 4. Time to Computed Tomography (CT) Scan or high-resolution CT of the chest

161 5. Average days between diagnostic order and completion date

162 6. Total number of referrals

163 7. Time to refer diagnosed patients to pulmonology and cardiology

164

165 1. Time to Echocardiogram: Breathlessness and cough are seen in many diseases that
166 commonly occur in middle-aged and elderly patients, most notably COPD and heart failure.
167 Echocardiograms can detect the presence of heart failure, cardiomyopathies, valve
168 abnormalities, and pulmonary hypertension thereby excluding important non-respiratory
169 causes of breathlessness.

170 2. Time to Chest X-ray: PCPs typically order chest x-rays in patients with respiratory
171 symptoms, such as shortness of breath and chronic cough; chest X-rays can provide clues to
172 the presence of conditions such as COPD, asthma and congestive heart failure. A primary
173 reason to obtain a chest radiograph in a patient with either a chronic cough or exertional
174 dyspnea is to exclude these and other alternative diagnoses including pneumonia,
175 pneumothorax, pleural effusion and lung masses. The suspicion of IPF should be raised in
176 patients with evidence of interstitial changes on CXR. These can be subtle and might be
177 missed with patients afforded a presumptive diagnosis of another more common condition
178 such as obstructive lung diseases or congestive heart failure.

179 3. Time to Spirometry: Spirometry is used to confirm a COPD diagnosis; in a primary care
180 setting, the diagnosis of COPD should be considered in patients who present with any
181 combination of breathlessness and chronic cough. Pulmonary function tests such as

182 spirometry can assess the nature and degree of lung involvement and differentiate between a
183 restrictive, obstructive or mixed physiologic pattern of impairment. Most interstitial lung
184 diseases such as IPF present as restrictive disorders, which is in contrast to obstructive
185 disorders such as asthma, COPD, and emphysema. Notably, patients with IPF can also
186 present with normal lung volumes and therefore normal spirometry does not exclude a
187 diagnosis of IPF.

188 4. Time to Computed Tomography (CT) Scan: A primary reason to obtain a CT scan of the
189 chest in a patient with either a chronic cough or exertional dyspnea is to discern specific
190 abnormalities that may be themselves be diagnostic, or at least guide subsequent testing
191 needed to attain a specific diagnosis. CT scan has greater sensitivity and specificity than
192 standard chest radiography.

193 5. Time to Referral to Pulmonologist: Once non-respiratory causes of breathlessness have been
194 excluded upon completion of a stepped diagnostic work-up, PCPs should consider the
195 possibility of IPF in middle-aged or elderly patients, who present with unexplained
196 symptoms of breathlessness or chronic cough. PCPs should refer patients to a pulmonologist
197 specialist to continue the work-up and confirm the diagnosis of IPF and differentiate this
198 from other causes of ILD.

199

200 **Outcome Data Collection**

201 Champions at each site were trained to enter data to a HIPAA compliant and personal health
202 information-secure cloud-based data capture platform that supports real-time reporting and
203 enables rapid-cycle process improvement. Data collection occurred between January 3 to June 1,
204 2018. Baseline data using these QI process change metrics were collected from each site upon

205 initiation of the QIE program and mapped to health system site data sources and clinical
206 workflows. Champions and administrators were able to review data trends on an aggregate level;
207 access to personal health information (PHI) was restricted to site Champions.

208

209 **Evaluation and Analysis**

210 Moore's outcomes provided the framework for analysis of educational outcomes.⁵ Ongoing
211 practice data derived from the Insight+ dashboard were used to describe processes changes and
212 changes in clinician practice.

213

214 **RESULTS**

215 **Participants**

216 Five sites that met the inclusion criteria were selected to participate in the QIE initiative with a
217 total of 24 clinicians. These sites had some familiarity with continuing education and QI process
218 change as well as engaged care teams with an interest in learning how to improve workflow
219 processes. All clinicians in each practice were invited to participate in the live webcast; however,
220 participation was tiered. All solo practitioners (n=3) completed the education webcast, two
221 clinicians from each of the larger practices (n=4) participated in the live webcast, and a recording
222 of the webcast and the slides were shared with the remaining clinicians in each practice (n=17).
223 At the request of the larger practice, we shared a recording and download of education materials
224 with their clinicians. This is an educational format that the larger practice has used in past QIE
225 interventions to enhance the scalability of the intervention and internal engagement of clinicians
226 in their practice. Although completion of the recorded webcast among the remaining clinicians
227 was not validated, feedback from ongoing weekly calls suggest that all clinicians in five


228 practices were exposed to the educational intervention. The total number of pre-pilot patients
229 was 100.

230

231 Accuracy of Diagnosis Coding

232 At baseline, 35% of patients (n=88) were accurately coded as having a diagnosis for SOB and
233 63% of patients were miscoded as having a diagnosis of chronic cough (Figure 1). In the pre-
234 pilot, some practices lacked clear attribute differentiation between SOB vs. chronic cough coding
235 and one practice was not coding at all for SOB at baseline. The education intervention clearly
236 addressed these issues and changed the accuracy of diagnosis coding. Following the
237 intervention, a significant increase in accuracy of SOB diagnosis coding (59%) occurred and
238 fewer patients had an inaccurate code for chronic cough (40%) in the pilot.

239



240


241

242 **Figure 1. Increase in Accuracy of (SOB) Diagnosis Coding with a Resulting Decrease in**
243 **Miscoding for Chronic Cough.**

244

245 **Time to Diagnostic Testing**

246 The number of average days decreased between first presentation in primary care and diagnostic
247 assessment via X-Ray, and CT scan (Figure 2). For example, X-ray ordering at baseline was 46
248 days. Following the educational intervention, x-rays were immediately ordered on the same day
249 as the initial primary care visit and the total number of x-rays appropriately ordered also
250 increased. Another positive process changes which occurred was adoption of PFT ordering by
251 the practices, as an appropriate diagnostic test. At baseline, there was a lack of awareness
252 regarding the importance of PFTs as an appropriate diagnostic tool. Per the educational
253 intervention, the use of PFT testing increased and was adopted by practices. The number of
254 average days also decreased for ordered CT diagnostics with sequential ordering and completion
255 of X-ray and PFT. As a result, linkages for appropriate care improved based on diagnostic test
256 type being ordered in a sequential timely manner, during the pilot and post educational
257 intervention.



258

259

260 **Figure 2. Average Days Between Initial PCP Visit and Ordering of Diagnostic Testing**

261


262 During pre-pilot, follow through on ordered diagnostics was inadequate or not optimal. In pilot,
 263 the number of average days decreased between the diagnostic order and completion date for X-
 264 ray, PFT and Echo (Figure 3). The educational intervention and training of staff played a
 265 significant role in reducing days to completing diagnostic orders. Practices implemented EHR
 266 alerts for outstanding orders, trained staff on the importance of the stepped-up diagnostic
 267 process, and to be more alert of overdue orders. Making sure the patient received coordinated
 268 care for timely follow-up of diagnostic testing not available in the office was also a focus of
 269 process improvements.

270

271 In pre-pilot, practices already had good existing workflows in place to manage other chronic

272 conditions and the data for days between diagnostic order and completion date was previously

273 available, since the practices were coding the data. However, the educational intervention trained
 274 practices to look at the right data and how to use the data. Practices became more effective at
 275 identifying care gaps with existing organizational workflows, which orders were overdue, and
 276 which patients need to be prompted for follow-up. The practice of regularly reviewing the data
 277 and applying a more population health approach was the resultant process change in the pilot.



278

279


280 **Figure 3. Decrease in Average Days Between Diagnostic Order and Completion Date**

281

282 **Time to Referral**

283 The time to referral decreased from pre-pilot baseline by 7 days for cardiology and 4 days for
 284 pulmonology (Figure 4). When compared to pre-pilot, this improvement in diagnosis and
 285 referral was due to better documentation and coding as well as shorter time periods for the initial
 286 order of appropriate diagnostic tests.

287



288

289

290 **Figure 4. Decrease in Time to Specialist Referral with Potential IPF-related Symptoms**

291

292 **DISCUSSION**

293 **Process Changes**

294 This QIE project raised the local index of suspicion for IPF in five primary care setting and
 295 increased the number of patients identified with SOB by 24%. The intervention improved
 296 accuracy of documentation for SOB and chronic cough diagnosis coding and reduced miscoding
 297 for chronic cough. At baseline, most practices were unable to clearly differentiate coding for
 298 SOB versus chronic cough and one practice had never coded for SOB. The live webcast
 299 emphasized how to differentiate between these symptoms and likely helped to raise awareness of
 300 IPF and differentiation between these two symptoms. The project improved the differential
 301 diagnosis for IPF, improved awareness and use of recommended diagnostic tools, and improved
 302 the timeliness of appropriate specialist referrals for patients with potential IPF symptoms.

303 Referrals to cardiology occurred 58% sooner than baseline and 24% sooner for pulmonology.
304 The linkage to appropriate care improved based on the type of testing being completed
305 appropriately and in a timely manner. At baseline, practices were unaware of the role of PFTs in
306 a stepped IPF work up. Following education, practices ordered PFT, chest x-ray, and CT scan
307 more expeditiously as appropriate diagnostic tools for patients with SOB and/or chronic cough.
308
309 Our study results show that more appropriate tests were being ordered compared with baseline;
310 however, our results do not reveal what happened in the seven days between patient visit and
311 PFT ordering, nor do our results indicate the sequence of test ordering. Therefore, results are
312 likely to reflect the availability of community resources, for instance, ordering an x-ray on the
313 day of visit and waiting for results before ordering PFT. There was also a trend toward more
314 rapid test completion (Figure 4). Raised awareness within participating practices about the need
315 for improving time to test request and specialist referral, as well as improved care coordination,
316 follow-up on ordered tests, and enhanced work flow processes already in place for other
317 conditions might explain this adoption of a more rapid, stepped approach to diagnosis. Providing
318 appropriate education on which symptoms to look for, which data to collect, and how to use
319 these data, may have enabled sites to identify care gaps such as overdue test orders and follow-
320 up. We were unable to determine significant differences in documentation and data exporting
321 process across practices; however, the documentation accuracy rate was higher and the time
322 taken to fulfill a referral was lower within the larger group. These differences might be due to the
323 existence of cross-training and more specialized roles in the larger group, such as a referral
324 specialist that primarily ensures that patients are being appropriately referred and that
325 appointments have been completed.

326

327 The Role of Data Transparency in Process Change

328 Overall, the project improved QI processes and data transparency concerning IPF and, in doing
329 so, illuminated a rare condition that participating sites had little knowledge of prior to the pilot.
330 By virtue of their PTN membership the practices in this pilot had already committed to building
331 a culture of process change and embraced the idea of using small projects as opportunities to
332 build QI skills that are conducive to process change. This project offered an additional
333 opportunity for participating practices to integrate population health concepts into the workflow
334 and consolidate a rapid cycle PDSA approach to creating and sustaining a quality-focused
335 organizational culture. The initiative was able to build on this established culture of QI to create
336 transparent data collection, coding, and documentation processes in the context of ongoing
337 education related specifically to IPF. The Dashboard enabled clinicians to know which
338 symptoms to be aware of in relation to IPF, which is an important resource given that IPF is rare
339 and many clinicians in primary care are unfamiliar with its presentation. Following education,
340 participants were able to use the Dashboard to share information about symptoms to be aware of
341 with clinic staff. Knowing that certain patient populations are potentially vulnerable to IPF
342 symptoms and knowing which symptoms potentially point to IPF were key process changes.

343

344 Study Strengths and Limitations

345 There are limitations to this study. The sample size was small for the number of participating
346 clinics and patients. However, given the rarity of IPF we did not expect to identify a large pool of
347 patients with potential IPF symptoms. Additionally, the QI Champion in one practice
348 transitioned to another practice. It would be prudent in future QIE initiatives to develop

349 opportunities for broader, cross-practice QI leadership training to mitigate gaps in QI leadership.
350 Despite these limitations, it was encouraging to see that busy primary groups were enthusiastic
351 about participating in a QIE project to learn more about a relatively rare condition as well as how
352 to better identify patients with IPF symptoms. This engagement is especially encouraging in an
353 area that does not yet have implications for QI reimbursement and is not considered a common
354 priority area.

355

356 **CONCLUSION**

357 Although IPF prevalence has been increasing in the US in recent years, current treatment
358 modalities can slow disease progression or prolong survival.⁷⁻⁹ Therefore, it is increasingly
359 important to refer patients for specialist evaluation earlier in their diagnostic journey. Consistent,
360 ongoing QIE offers an effective intervention to improve processes that support more rapid
361 referral to pulmonology and earlier consideration of therapy.

362

363 **Lessons for Practice**

364

- 365 • QIE is an effective intervention to improve processes and data transparency concerning
366 IPF in primary care.
- 367 • Education focused on which symptoms to look for, which data to collect, and how to use
368 these data, and may have enabled sites to identify care gaps such as overdue test orders
369 and follow-up.
- 370 • In the setting of IPF, QIE improved the differential diagnosis for IPF, raised awareness
371 and use of recommended diagnostic tools, and enhanced the timeliness of appropriate
372 specialist referrals for patients with potential IPF symptoms.

373

374

375 **REFERENCES**

376

- 377 1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement:
378 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
379 *Am J Respir Crit Care Med.* 2011;183(6):788-824.
- 380 2. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with
381 similarities and links to cancer biology. *Eur Respir J.* 2010;35(3):496-504.
- 382 3. Esposito DB, Lanes S, Donneyong M, et al. Idiopathic Pulmonary Fibrosis in United
383 States Automated Claims. Incidence, Prevalence, and Algorithm Validation. *Am J Respir*
384 *Crit Care Med.* 2015;192(10):1200-1207.
- 385 4. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare
386 beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. *The*
387 *Lancet Respiratory medicine.* 2014;2(7):566-572.
- 388 5. Moore DE GJ, Gallis HA. Achieving desired results and improved outcomes: integrating
389 planning and assessment throughout learning activities. *JCEHP.* 2009;29:1-15.
- 390 6. Yu YF, Wu N, Chuang CC, et al. Patterns and Economic Burden of Hospitalizations and
391 Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis. *Journal of*
392 *managed care & specialty pharmacy.* 2016;22(4):414-423.
- 393 7. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in
394 patients with idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;370(22):2083-2092.
- 395 8. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic
396 pulmonary fibrosis. *N Engl J Med.* 2014;370(22):2071-2082.

- 397 9. Raghu G, Rochweg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical
398 Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011
399 Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2015;192(2):e3-19.
- 400 10. Collard HR, Tino G, Noble PW, et al. Patient experiences with pulmonary fibrosis.
401 *Respir Med.* 2007;101(6):1350-1354.
- 402 11. Zibrak JD, Price D. Interstitial lung disease: raising the index of suspicion in primary
403 care. *NPJ Prim Care Respir Med.* 2014;24:14054.
- 404 12. Lee AS, Mira-Avendano I, Ryu JH, Daniels CE. The burden of idiopathic pulmonary
405 fibrosis: an unmet public health need. *Respir Med.* 2014;108(7):955-967.
- 406 13. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-
407 depth qualitative survey of European patients. *Chronic respiratory disease.*
408 2011;8(4):225-231.
- 409 14. Nathan SA BW, King CS. Guide to Clinical Management Idiopathic Pulmonary Fibrosis.
410 In: Switzerland: Springer 2016.
- 411 15. Diamond L KJ, Sulkes D. *The Quality Improvement Education (QIE) Roadmap: A*
412 *Pathway to our Future* The Alliance for Continuing Education in the Health Professions
413 2015.
- 414 16. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. Squire 2.0
415 (Standards for Quality Improvement Reporting Excellence): revised publication
416 guidelines from a detailed consensus process. *American journal of critical care : an*
417 *official publication, American Association of Critical-Care Nurses.* 2015;24(6):466-473.

- 418 17. Prevention. UCfDCa. Chronic obstructive pulmonary disease (COPD). Work-Related
419 Lung Disease (WoRLD) Surveillance System. <http://www.cdc.gov/copd/data.htm>.
420 Accessed.
421